Shanghai Medicilon Inc.

Medicilon has built a one-stop research platform for the preclinical R&D of cellular immunotherapies, covering a variety of immunotherapy methods including CAR-T, TCR-T and CAR-NK. Using a wealth of animal models and a variety of advanced analysis techniques, comprehensively considering the characteristics of different research projects, Medicilon has completed numerous pre-clinical projects for clients worldwide. Cellular immunotherapy has developed by leaps and bounds in recent years, providing a cure for many difficult-to-treat cancers.  With the continuous discovery of tumor targets and mechanisms, the track is still full of vitality and hope bringing new breakthroughs in tumor treatment and human welfare. Medicilon has built a one-stop research platform for the preclinical R&D of cellular immunotherapies, covering a variety of immunotherapy methods including CAR-T, TCR-T and CAR-NK.  Using a wealth of animal models and a variety of advanced analysis techniques, c...